The appointment of Dr Nam Park as Chief Business Officer brings further expertise in venture financing and capital markets to Oxford Vacmedix
Oxford, UK – 16th January 2025
Press Release – Appointment of Dr Nam Park 16-Jan-25
Oxford Vacmedix (OVM), the UK-based biopharma company focused on development of therapeutic cancer vaccines, announced today that Dr Nam Park, who has extensive experience and knowledge of finance and science, will join the company’s Management Team as Chief Business Officer. Nam previously worked with the company in an external capacity and was instrumental in raising Series A funding for OVM from investors in South Korea and China. In his new role he will take the lead in raising finance as well as contributing to the management and growth of the company.
William Finch, Chief Executive Officer of Oxford Vacmedix said:
I am delighted to welcome Nam to Oxford Vacmedix at this critical time as we advance our vaccines in the clinic. Nam has many years of valuable experience in venture financing and capital markets as well as considerable management expertise in biotech. As a member of the Management Team, he will play a key role in raising funds as we build our portfolio to develop effective vaccines that address the unmet medical needs of cancer patients.
Nam gained a BSc in Physics and a PhD in Biophysics from Imperial College in London and was a Fellow of the Royal Microscopy Society. He has worked in London, New York, Hong Kong and Seoul in a number of banking and securities roles for Standard Chartered Bank, ING Baring Securities, Paribas Asia Equity and Hyundai Securities. In 2000 Nam joined HSBC and over the following fifteen years held senior equity research roles, finishing as Regional Head of Healthcare for Asia. During his career Nam was involved with many initial public offerings of leading healthcare and tech firms in Asia.
After HSBC Nam worked as Managing Director – Sales in Aetas in Hong Kong, succeeding in raising over USD120m for small and mid-size biotech and tech companies in Europe and the Asia Pacific region. More recently he was Executive Vice President at Medpacto, a listed Korean biotech, with operational responsibility and leading a successful rights issue of KRW74bn (approx. USD50m).
Dr Nam Park commented:
Having already worked with the team at Oxford Vacmedix for several years I am very pleased to now join the Company as Chief Business Officer. Cancer vaccines based on OVM’s ROP technology offer great hope to provide safe and effective therapies to help people with cancer live longer and better lives, and I very much look forward to making a positive contribution to the company.

END
For more information or to express an interest in investing in Series B, please contact:
William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 742087 | M: +44(0)7769 903711 | E: wfinch@oxfordvacmedix.com
Notes to Editor
About Oxford Vacmedix
Oxford Vacmedix UK Ltd, based at the Oxford Science Park, UK, is a bio-pharma company that was spun out from the University of Oxford’s Department of Oncology and is utilising the novel proprietary platform technology of recombinant overlapping peptide (ROP) invented by Professor Shisong Jiang. ROP has been validated as a technology to stimulate broad and strong T cell immunity, therefore forming a good platform for therapeutic vaccines and diagnostics in cancer and infectious diseases.
The technology uses the novel, proprietary platform of ROP to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways, and synergy when used in combination with other immune oncology (IO) agents. The company has extensive contacts and collaborations in China through Changzhou Bioscience Group (CBIG) that is using the ROP platform for diagnostics in both cancer and infectious diseases.
Vaccines
OVM is developing two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeting cervical cancer and head and neck cancer. OVM-200 targets survivin, a protein overexpressed by cancer cells that allow unregulated growth, which stimulates an immune response. The vaccine is in a Phase 1 trial in the UK which is both the first time OVM-200 has been used in people and also the first time any ROP (Recombinant Overlapping Peptide) based vaccine has been tested in the clinic. The ongoing trial is focused on safety and on establishing an immune response in advanced cancer patients in three cancer indications: non-small-cell lung cancer (NSCLC), prostate cancer, and ovarian cancer. Initial results from Phase 1a, the dose escalation part of the trial, have shown very good safety and a strong immune response.
OVM secured Series A and more recently lead Series B investment from Dx&Vx (formerly Cancer ROP), a listed South Korean biotech company, and from other existing shareholders. The company is currently seeking further Series B funding to advance OVM-200 to Phase 2 and OVM-100 into Phase 1 trials, as monotherapy and also in combination. In addition, the option of using mRNA delivery with the ROP technology is also being explored.
For more information: https://www.oxfordvacmedix.com